✦ LIBER ✦

15: Results of a 12-Month, Multicenter, Randomized Trial of Everolimus with Reduced-Exposure Cyclosporine Versus MMF and Standard-Exposure Cyclosporine in De Novo Cardiac Transplant Recipients

✍ Scribed by H. Lehmkuhl; U. Livi; J. Arizon; M. Viganò; C. Magelli; P. Boissonnat; G. Gerosa; F. Musumeci; I. Gandjbakhch; J. Vanhaecke; J.M. Hexham; K.C. Mange

Book ID: 116520323
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 112 KB
Volume: 27
Category: Article
ISSN: 1557-3117
DOI: 10.1016/j.healun.2007.11.019

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

397: Everolimus with reduced cyclosporin

397: Everolimus with reduced cyclosporine exposure vs. MMF and conventional cyclosporine: Results from a study in de novo heart transplant recipients

✍ H. Lehmkuhl; U. Livi; P. Boissonnat; J. Arizon; M. Vigano; C. Magelli; L. Almena 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 70 KB

12-month safety and efficacy of everolim

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

✍ Helio Tedesco-Silva Jr; Stefan Vitko; Julio Pascual; Josette Eris; John C. Magee 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 504 KB

55 Everolimus with Reduced CsA vs MMF wi

55 Everolimus with Reduced CsA vs MMF with Standard CsA Exposure in De Novo Heart Transplant Recipients: 12 Month Efficacy and Safety Analysis

✍ H. Eisen; D. Pauly; R. Starling; H. Lehmkuhl; H. Ross; A. Kfoury; S. Wang; B. Ca 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 289 KB

466: Hospitalization Days Due to Major C

466: Hospitalization Days Due to Major Cardiac Events (MACE) in De Novo Heart Transplant Recipients: Data from a 12-Month, Multicenter, Randomized Trial of Everolimus Versus MMF

✍ H. Lehmkuhl; J. Arizon; L. Almenar; C. Magelli; G. Gerosa; S. Varnous; F. Musume 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 69 KB

171 Lower Incidence of Viral Infections

171 Lower Incidence of Viral Infections with Everolimus Versus MMF in De Novo Heart Transplant Recipients: 12 Month Analysis of a Randomized Multicenter Study

✍ H. Ross; A.G. Kfoury; A. Van Bakel; G. Ewald; J. Burton; A. Andreassen; J. Segov 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 75 KB

Efficacy and safety of de novo or early

Efficacy and safety of de novo or early everolimus with low cyclosporine in deceased-donor kidney transplant recipients at specified risk of delayed graft function: 12-month results of a randomized, multicenter trial

✍ Jacques Dantal; François Berthoux; Marie-Christine Moal; Lionel Rostaing; Christ 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 335 KB